We are thrilled to announce James W. Stark, MD, FAAN has recently been selected as a Castle Connolly Top Doctor in the field of Neurology. The Castle Connolly physician-led research team reviews and screens all nominated physicians before selecting those...
moreHappy Mother's Day from the IMSMP! We hope you have a wonderful day with friends and family!
The IMSMP wishes all who observe Ramadan with their family and loved ones, a healthy and blessed holiday.
Why should I join a support group? “I don’t like hearing other’s sob stories”, “I’m shy”, “I don’t like speaking in groups”, “I don’t have time”. Can you relate? I am sure every person who belongs to a support group had one or more of these thoughts before they took the plunge. The main purpose of a support group is for members to feel heard, understood and cared for. Members’ feedback validates emotional reactions — even through laughter when frustrations or anecdotes strike a chord (...
moreMore than just a pretty smile, maintaining optimal oral health is essential for staying healthy. The oral cavity has a unique composition of healthy bacteria and yeasts commonly called “normal flora.” The balance of organisms can easily be altered by systemic illness, treatments, or poor oral hygiene. Even individuals with ideal physical and mental health can be challenged in their pursuit of optimal oral health. People with complicated medical and/or mental health problems have a greater...
moreWe are pleased to announce, Dr. James W. Stark, Assistant Medical Director and Director of Clinical Trials at the International Multiple Sclerosis Management Practice (IMSMP) has been elected a Fellow Member of the American Academy of Neurology (AAN). This outstanding achievement recognizes the contributions Dr. Stark has made to the Academy and to the neurology community. To receive this prestigious honor, accomplishments both academically and clinically were taken into consideration. These...
moreThe FDA has announced approval of the oral drug, Mayzent (siponimod) for the treatment of clinically isolated syndrome, relapsing-remitting MS as well as for active secondary progressive MS. Mayzent (siponimod) comes from the same family of drugs as Gilenya (fingolimod), however Mayzent binds to more specific receptors in the body. This means that we believe this new drug will be just as effective as Gilenya but should have fewer side effects and adverse reactions. Mayzent should be...
moreFor those living with multiple sclerosis, seasonal temperatures can have a major impact. With the spring season approaching, Healthline published an article on seasonal "zingers" in MS and featured our very own Dr. Stark as an expert in the field!
To read the article, please click here.
...
For Immediate Release
New York, NY – March 11, 2019 – Tisch MS Research Center of New York (Tisch MSRCNY) today announced that...
moreThe March issue of Vanity Fair features actress and IMSMP patient Selma Blair discussing her battle with multiple sclerosis transforming her into the warrior she is today. We are proud to share her interview here:
https://www.vanityfair.com/hollywood/2019/02/selma-blairs-transformation
...
moreBecause you deserve only the best in MS healthcare. Experience the difference.
Join our mailing list today! Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.
* We don’t share your information with anyone.
